The new potential antipsychotic drug BMY 20661 was subjected to a series of electrophysiological tests to determine its effects on midbrain dopamine (DA) neurons in the rat substantia nigra pars compacta (A9) and ventral tegmental area (AlO). Acute intravenous (i.v.) administration of BMY 20661 exer
The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects
✍ Scribed by Dr. O. Svendsen; J. Arnt; V. Boeck; K. P. Bøgesø; A. V. Christensen; J. Hyttel; J.-J. Larsen
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 768 KB
- Volume
- 7
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Changes in dopamine (DA) D~1~, D~2~, D~3~, and D~4~ receptors and serotonin 5‐HT~1A~ and 5‐HT~2A~ receptors in rat forebrain regions were autoradiographically quantified after continuous infusion of JL 13 [(5‐(4‐methylpiperazin‐1‐yl)‐8‐chloro‐pyrido[2,3‐__b__][1,5]benzoxazepine fumarate
The in vivo dopamine (DA) receptor binding and behavioural properties of the recently characterised putative preferential DA autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 were studied in rats with a unilateral 6-OH-DA lesion of the substantia nigra. The main findings were a) that (+)-UH 232 and